San Francisco, CA – Iodine.com, the crowd-sourced medication review site founded by former Wired editor Thomas Goetz and former Google engineer Matt Mohebbi, is recruiting participants for a study on the effects of antidepressants. The really interesting part: The results will tell the participants if their individual drugs are working.
The project is called Iodine Timeline. For one month, each participant answers email surveys about mood, appetite, sleep and weight gain. Then, they get meaningful peer context in a personalized report that helps them understand how their drug is working compared to the hundreds of thousands of other participants.
Iodine wants to ultimately be able to set expectations about when particular antidepressants can be expected to kick in as well as the severity and frequency of side effects.
Goetz and team are hoping the social platform can bring some scale to our understanding of antidepressants. More than 30 million Americans take them, they say, but the largest study conducted to-date included just 4,041 people.
About the Author:
As Managing Director of Innovation and Insights for Syneos Health Communications, Leigh is responsible for building and scaling a global team of healthcare experts who together help life science leaders better understand the complex lives, influences and expectations of their customers. Specifically, they uncover actionable insights that fuel empathy and creativity; lead co-creation events that let marketers learn from peers, trends, and new possibilities; and help clients identify the most valuable and useful new customer experiences to create.
Leigh has worked with Fortune 1000 companies to craft their digital, mobile, social and CRM strategies for nearly 20 years.She’s worked for category-leading agencies in retail, public affairs, B2B technology, and higher education. Prior to moving to Syneos Health Communications, she held several leadership roles at our largest agency, GSW. There, she founded an innovation practice fueled by the zeitgeist and spearheaded digital and innovation thinking across the business.
Leigh has taken a special interest in complex healthcare products that can change lives in meaningful ways. She was recently a strategic lead on the 3rd largest launch in pharmaceutical history: Tecfidera. Before that she had keys roles with Eli Lilly Oncology, Abbott Nutrition, Amgen Cardiovascular, and Eli Lilly Diabetes.
A critical part of Leigh’s work is trends and new ideas. Every year, she convenes a group of trend watchers from across our global network to identify the shifts most critical to healthcare marketers. This year, she led over 250 experts to experts to focus on the most important changes in the commercial, consumer, marketing, digital and healthcare landscapes. (See reports at trends.health)
Leigh is a sought-after writer and speaker. Recognized as one of the most inspiring people in the pharmaceutical industry by PharmaVoice and Top 10 Innovation Catalysts of 2017 by MM&M, Leigh also was recognized as a Rising Star by the Healthcare Businesswomen's Association (HBA) for her overt passion, industry thought leadership and significant contributions in new business, strategy and mentoring.
